subscribeSubscribe
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
PRESS RELEASE
14 Feb 2024
Share Share
Ipsen announces U.S. FDA submission acceptance of its sN DA for Onivyde

Ipsen announces U.S. FDA submission acceptance of its sN DA for Onivyde
GLOBENEWSWIRE
14 Jun 2023
Share Share
Edison Oncology Announces Presentation of Two Scientific Posters at AACR Meeting

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Meeting
PR NEWSWIRE
20 Apr 2023
Share Share
Ipsen`s Onivyde turns in positive results in pancreatic cancer

Ipsen`s Onivyde turns in positive results in pancreatic cancer
Zoey Becker FIERCE PHARMA
21 Jan 2023
Share Share
RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial

RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
PRNEWSWIRE
14 Dec 2022
Share Share
Ipsen to File sNDA for Pancreatic Cancer Drug Following Positive PhIII Results

Ipsen to File sNDA for Pancreatic Cancer Drug Following Positive PhIII Results
Alex Keown BIOSPACE
10 Nov 2022
Share Share
Onivyde® Regimen Demonstrated Significant Improvement in Overall Survival

Onivyde® Regimen Demonstrated Significant Improvement in Overall Survival
BUSINESSWIRE
09 Nov 2022
Share Share
Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde
Phil Taylor PHARMAPHORUM
04 Aug 2022
Share Share
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde
BUSINESSWIRE
03 Aug 2022
Share Share
An anticancer drug made to increase efficacy and decrease side effects

An anticancer drug made to increase efficacy and decrease side effects
ARIRANG
23 May 2022
Share Share